Cancer patient fears sufferers will be ‘cut off in their prime’ as lifeline drug is axed to save money
- Credit: Lucy Taylor
A Suffolk man is calling for people to sign a petition to reinstate a life-extending cancer drug.
Tim Mason, 57, from Ipswich, has suffered from advanced Gastrointestinal Stromal Tumour (GIST) for 10 years, and uses the drug regorafenib to manage his condition.
The Cancer Drugs Fund (CDF) has withdrawn the product from its approved list, meaning although Mr Mason will continue to receive the drug, those who are diagnosed with the disease in the future will not be able to access it.
Regorafenib is a ‘third line’ drug, after first and second line drugs imatinib and sunitinib.
In January the CDF said the withdrawal, along with other drugs was part of creating projected savings of about £80million through a combination of negotiated price reductions and improved clinical effectiveness.
You may also want to watch:
Mr Mason is a trustee of GIST Support UK, which is attempting to get 100,000 signatures on a petition to the government by March 30.
Mr Mason said the body and the cancer “learns to outsmart” the first and second line drugs, and without regorafenib, he would “really be struggling by now”.
- 1 Tories retain Suffolk County Council control - but Greens make huge gains
- 2 A weekend of potential departures as Town finish up their disappointing season
- 3 Joy as council reverses ban on motorhomes in car parks
- 4 See inside beautiful stately home near Ipswich - for one day only
- 5 'Masterpiece' modernist home with panoramic sea views for sale for £850,000
- 6 'Complete shock' - Neighbours stunned after cannabis farm uncovered
- 7 Bookings now open for unique new Suffolk dining experience
- 8 Elections 2021: Tim Passmore re-elected Suffolk Police and Crime Commissioner
- 9 Poorly rated Chick King takeaway goes into liquidation
- 10 Inside Suffolk's own Repair Shop
He added: “People who can’t get the drug but are needing it are in dire trouble.”
The cancer, although rare, regularly affects younger people.
Withdrawal of the drug would “potentially cut people off in the prime of life,” said Mr Mason.
“It’s such a successful drug, it made my quality of life much better.
“The side effects are much less than the second line drug and as far as we know, there are no drugs in the pipeline which could do what regorafenib does.”
To sign the petition visit epetitions.direct.gov.uk/petitions/73911